GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TYK Medicines Inc (HKSE:02410) » Definitions » 3-Year Revenue Growth Rate

TYK Medicines (HKSE:02410) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TYK Medicines 3-Year Revenue Growth Rate?

TYK Medicines's Revenue per Share for the three months ended in Dec. 2024 was HK$0.00.

During the past 12 months, TYK Medicines's average Revenue per Share Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of TYK Medicines's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, TYK Medicines's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TYK Medicines's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where TYK Medicines's 3-Year Revenue Growth Rate falls into.


;
;

TYK Medicines 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


TYK Medicines  (HKSE:02410) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


TYK Medicines 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of TYK Medicines's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


TYK Medicines Business Description

Traded in Other Exchanges
N/A
Address
No. 1278 Mingzhu Road, Room 1403-2, Floor 14, Tower A, Changxing World Trade Building, Zhejiang Province, Changxing Economic Development Zone, Huzhou, CHN
TYK Medicines Inc is a drug discovery research and development centre. The company and its subsidiaries are principally engaged in the research, development and commercialization of pharmaceutical products.
Executives
Nan Jing Yi Da Tou Zi Guan Li You Xian Gong Si
Nan Jing Yi Da Zi Ben Guan Li Qi Ye You Xian He Huo
Jiang Su Yi Da Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si
Wu Yusheng 2201 Interest of corporation controlled by you
Zhu Julia Ming 2202 Interest of your spouse
Zheng Zhou Tai Ji Hong Nuo Yi Yao Gu Fen You Xian Gong Si 2101 Beneficial owner
Zhang Xing Li Yuan Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
He Chao 2201 Interest of corporation controlled by you
Bei Jing Hou Ji Jing Qiao Chuang Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Rong Chen Hou Ji Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Zhang Xing Xing Zhang Chan Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

TYK Medicines Headlines

No Headlines